NASDAQ:VNDA Vanda Pharmaceuticals - VNDA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $6.79 +0.08 (+1.19%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$6.73▼$6.8350-Day Range$6.18▼$7.8352-Week Range$6.05▼$12.34Volume635,185 shsAverage Volume591,569 shsMarket Capitalization$385.54 millionP/E Ratio56.59Dividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Vanda Pharmaceuticals MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish4.83% of Float Sold ShortDividend StrengthN/ASustainability-1.77Upright™ Environmental ScoreNews Sentiment0.63Based on 2 Articles This WeekInsider TradingSelling Shares$290,324 Sold Last QuarterProj. Earnings Growth-35.14%From $0.37 to $0.24 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.15 out of 5 starsMedical Sector438th out of 1,004 stocksPharmaceutical Preparations Industry201st out of 489 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Vanda Pharmaceuticals. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.83% of the float of Vanda Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVanda Pharmaceuticals has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Vanda Pharmaceuticals has recently increased by 8.23%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVanda Pharmaceuticals does not currently pay a dividend.Dividend GrowthVanda Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVanda Pharmaceuticals has received a 61.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Tasimelteon", "Antipsychotics", and "Clinical research services for psychotic disorders" products. See details.Environmental SustainabilityThe Environmental Impact score for Vanda Pharmaceuticals is -1.77. Previous Next 2.6 News and Social Media Coverage News SentimentVanda Pharmaceuticals has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Vanda Pharmaceuticals this week, compared to 1 article on an average week.Search Interest5 people have searched for VNDA on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vanda Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $290,324.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of Vanda Pharmaceuticals is held by insiders.Percentage Held by Institutions97.22% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Vanda Pharmaceuticals are expected to decrease by -35.14% in the coming year, from $0.37 to $0.24 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vanda Pharmaceuticals is 56.59, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 129.25.Price to Earnings Ratio vs. SectorThe P/E ratio of Vanda Pharmaceuticals is 56.59, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 116.81.Price to Book Value per Share RatioVanda Pharmaceuticals has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Vanda Pharmaceuticals (NASDAQ:VNDA) StockVanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.Read More Receive VNDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address VNDA Stock News HeadlinesMarch 30, 2023 | bizjournals.comVanda Pharmaceuticals wins lawsuit against FDAMarch 28, 2023 | finance.yahoo.comVanda Prevails in Jet Lag Litigation Against the FDAApril 1, 2023 | Porter & Company (Ad)Biden’s Big Lie…Biden is about to steal the 2024 election... Not through voter suppression, collision with Big Tech, or anything else you might be thinking of. February 26, 2023 | benzinga.comVanda Pharma Stock (NASDAQ:VNDA), Quotes and News SummaryFebruary 10, 2023 | msn.comVanda Pharmaceuticals's Return On Capital Employed InsightsFebruary 9, 2023 | fool.comWhy Vanda Pharmaceuticals Stock Crawled Higher TodayFebruary 9, 2023 | finanznachrichten.deVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial ResultsFebruary 8, 2023 | finance.yahoo.comVanda Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial ResultsApril 1, 2023 | Porter & Company (Ad)A strange force is brewing…An economic force with the potential to be bigger than the 1880s railroad boom, the 1920s automobile boom, the baby boom of the 1960s, or the Dotcom boom of the ‘90s. And while Biden has nothing to do with it… he’ll take full credit. February 7, 2023 | msn.comEarnings Preview: Vanda PharmaceuticalsFebruary 1, 2023 | finance.yahoo.comVanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 8, 2023January 12, 2023 | finance.yahoo.comAre Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?January 6, 2023 | finance.yahoo.comVanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare ConferenceDecember 19, 2022 | markets.businessinsider.comVanda Pharma: Phase III Study Shows Potential Of Fanapt In Treating Bipolar I DisorderDecember 16, 2022 | finance.yahoo.comVanda Pharmaceuticals Provides an Update to HETLIOZ® ANDA Litigation Appeal: Federal Circuit grants motion to temporarily enjoin generic launchDecember 14, 2022 | finance.yahoo.comVanda Pharmaceuticals gets bad news in generic competition court rulingDecember 13, 2022 | marketwatch.comVanda Pharmaceuticals Shares Tumble After Loss in Hetlioz Patent Suit >VNDADecember 13, 2022 | finance.yahoo.comVanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA LitigationDecember 5, 2022 | finance.yahoo.comVanda Pharmaceuticals is testing a drug for performance anxiety. It just got good news.December 2, 2022 | seekingalpha.comVanda says performance anxiety drug lowered stress in Phase 2 enrolleesDecember 2, 2022 | finance.yahoo.comVanda Pharmaceuticals Reports Results in a Phase II Clinical Study of VQW-765 in the Treatment of Acute Performance AnxietyNovember 9, 2022 | finance.yahoo.comVanda Pharmaceuticals Third Quarter 2022 Earnings: Misses ExpectationsNovember 9, 2022 | finance.yahoo.comVanda Pharmaceuticals Announces Participation at November 2022 Investor ConferencesNovember 4, 2022 | finance.yahoo.comVanda Pharmaceuticals is spending big on R&D. Here’s what it has on tap for 2023.November 2, 2022 | finance.yahoo.comVanda Pharmaceuticals Reports Third Quarter 2022 Financial ResultsNovember 2, 2022 | finance.yahoo.comVanda Pharmaceuticals (VNDA) Lags Q3 Earnings and Revenue EstimatesOctober 26, 2022 | finance.yahoo.comVanda Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VNDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address VNDA Company Calendar Last Earnings11/03/2021Today3/31/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:VNDA CUSIP92165910 CIK1347178 Webwww.vandapharma.com Phone(202) 734-3400Fax202-296-1450Employees278Year Founded2002Profitability EPS (Most Recent Fiscal Year)$0.12 Trailing P/E Ratio56.59 Forward P/E Ratio18.35 P/E GrowthN/ANet Income$6.28 million Net Margins2.47% Pretax Margin4.44% Return on Equity1.22% Return on Assets1.02% Debt Debt-to-Equity RatioN/A Current Ratio5.68 Quick Ratio5.67 Sales & Book Value Annual Sales$254.38 million Price / Sales1.52 Cash Flow$0.11 per share Price / Cash Flow63.56 Book Value$9.32 per share Price / Book0.73Miscellaneous Outstanding Shares56,780,000Free Float52,810,000Market Cap$385.54 million OptionableOptionable Beta0.72 Social Links Key ExecutivesMihael Hristos PolymeropoulosChairman, President & Chief Executive OfficerKevin MoranChief Financial Officer, Treasurer & SVPTim WilliamsSecretary, Senior VP & General CounselKim WijkstromSenior Vice President & Chief Marketing OfficerGunther BirznieksSenior Vice President-Business DevelopmentKey CompetitorsLexicon PharmaceuticalsNASDAQ:LXRXEmergent BioSolutionsNYSE:EBSXOMANASDAQ:XOMARigel PharmaceuticalsNASDAQ:RIGLIntercept PharmaceuticalsNASDAQ:ICPTView All CompetitorsInsiders & InstitutionsMihael Hristos PolymeropoulosSold 22,426 sharesTotal: $139,713.98 ($6.23/share)Kevin Patrick MoranSold 7,966 sharesTotal: $49,867.16 ($6.26/share)Joakim WijkstromSold 7,720 sharesTotal: $48,095.60 ($6.23/share)Timothy WilliamsSold 8,437 sharesTotal: $52,646.88 ($6.24/share)Voya Investment Management LLCBought 31,588 shares on 2/28/2023Ownership: 0.204%View All Insider TransactionsView All Institutional Transactions VNDA Stock - Frequently Asked Questions How have VNDA shares performed in 2023? Vanda Pharmaceuticals' stock was trading at $7.39 at the beginning of 2023. Since then, VNDA stock has decreased by 8.1% and is now trading at $6.79. View the best growth stocks for 2023 here. When is Vanda Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our VNDA earnings forecast. How were Vanda Pharmaceuticals' earnings last quarter? Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced its earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.20 by $0.06. The biopharmaceutical company earned $70.10 million during the quarter, compared to the consensus estimate of $73.50 million. Vanda Pharmaceuticals had a trailing twelve-month return on equity of 1.22% and a net margin of 2.47%. During the same quarter in the previous year, the business posted $0.11 earnings per share. What ETFs hold Vanda Pharmaceuticals' stock? ETFs with the largest weight of Vanda Pharmaceuticals (NASDAQ:VNDA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), iShares Neuroscience and Healthcare ETF (IBRN), Invesco S&P SmallCap Health Care ETF (PSCH), First Trust Active Factor Small Cap ETF (AFSM), Invesco Nasdaq Future Gen 200 ETF (QQQS), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO? 12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Vanda Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX). What is Vanda Pharmaceuticals' stock symbol? Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA." Who are Vanda Pharmaceuticals' major shareholders? Vanda Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (5.11%), Dimensional Fund Advisors LP (5.04%), Millennium Management LLC (3.15%), Assenagon Asset Management S.A. (2.81%), Epoch Investment Partners Inc. (2.47%) and Macquarie Group Ltd. (2.33%). Insiders that own company stock include Aranthan Jones II, Gunther Birznieks, Joakim Wijkstrom, Kevin Patrick Moran, Melissa Young, Mihael Hristos Polymeropoulos, Phaedra Chrousos, Richard W Dugan, Stephen Ray Mitchell, Thomas Watkins and Timothy Williams. View institutional ownership trends. How do I buy shares of Vanda Pharmaceuticals? Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Vanda Pharmaceuticals' stock price today? One share of VNDA stock can currently be purchased for approximately $6.79. How much money does Vanda Pharmaceuticals make? Vanda Pharmaceuticals (NASDAQ:VNDA) has a market capitalization of $385.54 million and generates $254.38 million in revenue each year. The biopharmaceutical company earns $6.28 million in net income (profit) each year or $0.12 on an earnings per share basis. How many employees does Vanda Pharmaceuticals have? The company employs 278 workers across the globe. How can I contact Vanda Pharmaceuticals? Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. The official website for the company is www.vandapharma.com. The biopharmaceutical company can be reached via phone at (202) 734-3400, via email at pr@vandapharma.com, or via fax at 202-296-1450. This page (NASDAQ:VNDA) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.